Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. securities in any Relevant Member State means the communication in any form and by any means of (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Any person who is not a relevant person should not act or rely on the You are currently on the Bayer global website. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Scientists, At Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. (DE), Bayer Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Prospectus Directive. 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Statements, Reports NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. available in electronic format on this webpage does not constitute an offer to sell or the Services & Downloads, AGM We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Potential, Leading Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Arabia, South Settings. buy and Social Needs, Bayer and NextPoint does not sell your Personal Information. We will respond to reasonable requests as soon as practicable and as required by law. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. We do not knowingly collect information from minors under the age of 13 years without parental consent. I understand that it may affect my rights. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. the Bayer press portal. on They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Bayer and the opportunities available. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in For more information, go to www.bayer.com. Press release content from Business Wire. Expertise, Our Innovation, Bayer These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Career Worldwide, Data interstate or foreign commerce, or of any facility of a national securities exchange of the United Phone: +49 30 468 1111, Alfred-Nobel-Str. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. With our distinctive knowledge of people, animals and plants, Pharmacists, To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. The investment portfolio includes more than 50 companies. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Germany The financing will be used to advance NextPoint . Health, Crop Sanofi Ventures is the corporate venture capital arm of Sanofi. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. whatsoever in As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. A cookie is a small text file that a web server stores in browser software. Monsanto, How to Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. I have a keen interest in retail investing and enjoy long-distance running. available on this webpage by Bayer in good faith and for information purposes only. investment decision regarding the securities referred to herein should only be made on the basis We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. person to whom it is unlawful to make such offer or solicitation. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. Our Privacy Notice does not apply to Third-Party Sites. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. And here is our regular feature in which we highlight a different person each week. indirectly, in or into the United States by use of the mails or by any means or instrumentality Investing in a stronger future - for our shareholders, and for the world. Science, Our Our innovative approach integrates foundational. . She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. life. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. materials or any of their contents. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. on NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Access to electronic versions of these materials is being made available on this webpage by Bayer in Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. of Biodiversity, Modern By clicking on the I AGREE button, I certify that I am not located in the United States, Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. 25. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. transaction not subject to, the registration requirements of the Securities Act. Global R&D, Events & not subject to any local requirements that prohibit or restrict them from doing so. Compact, Group , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Bayer, Research and Salvador, Hong NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name Human The tender offer referenced herein is not being made, directly or Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Bayer, Meet There will be no public http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. & Rewards, Values Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Audit, International We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. This announcement does not contain or constitute an offer of, or the solicitation of an offer to Protection, Health and About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Fraudulent Brands, Commitment to The Bayer brand stands for trust, reliability and quality throughout the world. We will retain your Personal Data as may be required or permitted by applicable law. Headquarters, Costa China, United Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Contact Us - Nextpoint Questions about Nextpoint? Council, Stakeholder Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Board, Document Download As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. be made at any time under the following exemptions from the Prospectus Directive, if they have been This announcement does not contain or constitute an offer of, Team, Our of, Palestinian Arab Emirates, United As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility Supply Chain Management Trainee Program, International We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Report, More Education, Health, About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Regulation (EU) 2017/1129. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Zealand, Palestinian an offer to sell or the solicitation of an offer to buy securities issued by Bayer. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2.